Incyte Corporation is a biotechnology business based in the US. Incyte Corporation shares (INCY) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $67.86 – a decrease of 1.06% over the previous week. Incyte Corporation employs 2,617 staff and has a trailing 12-month revenue of around $4.4 billion.
Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.
Must be a SoFi Plus member at the time a recurring deposit is received into your SoFi Active or Automated investing account to qualify. Bonus calculated on net monthly recurring deposits made via ACH and paid out as Rewards Points. See Rewards Terms of Service. SoFi reserves the right to change or terminate this promotion at any time without notice. See terms and limitations. https://www.sofi.com/sofiplus/invest/#disclaimers
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – INCY.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Incyte Corporation stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
7 of 7
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Incyte Corporation stock price (NASDAQ: INCY)
Use our graph to track the performance of INCY stocks over time.
Is it a good time to buy Incyte Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Incyte Corporation price performance over time
Historical closes compared with the close of $67.86 from 2025-07-18
1 week (2025-07-11)
-1.06%
1 month (2025-06-20)
-0.88%
3 months (2025-04-17)
16.58%
6 months (2025-01-17)
-5.66%
1 year (2024-07-19)
3.02%
2 years (2023-07-20)
6.01%
3 years (2022-07-20)
82.49
5 years (2020-07-17)
104.11
Is Incyte Corporation stock undervalued or overvalued?
Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Incyte Corporation's P/E ratio
Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 343x. In other words, Incyte Corporation shares trade at around 343x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Incyte Corporation's PEG ratio
Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1233. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Incyte Corporation's EBITDA
Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $303.3 million.
The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.
Incyte Corporation financials
Revenue TTM
$4.4 billion
Operating margin TTM
20.65%
Gross profit TTM
$1.6 billion
Return on assets TTM
2.04%
Return on equity TTM
0.47%
Profit margin
0.48%
Book value
$18.93
Market Capitalization
$13.3 billion
TTM: trailing 12 months
Incyte Corporation's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Incyte Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Incyte Corporation's total ESG risk score
Total ESG risk: 29.4
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Incyte Corporation's overall score of 29.4 (as at 12/31/2018) is nothing to write home about – landing it in it in the 48th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Incyte Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Incyte Corporation's environmental score
Environmental score: 7.61/100
Incyte Corporation's environmental score of 7.61 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Incyte Corporation's social score
Social score: 24.73/100
Incyte Corporation's social score of 24.73 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Incyte Corporation's governance score
Governance score: 12.56/100
Incyte Corporation's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Incyte Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Incyte Corporation's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Incyte Corporation scored a 1 out of 5 for controversy – the highest score possible, reflecting that Incyte Corporation has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Incyte Corporation was last rated for ESG on: 2019-01-01.
Total ESG score
29.4
Total ESG percentile
47.86
Environmental score
7.61
Environmental score percentile
8
Social score
24.73
Social score percentile
8
Governance score
12.56
Governance score percentile
8
Level of controversy
1
Incyte Corporation share dividends
We're not expecting Incyte Corporation to pay a dividend over the next 12 months.
Have Incyte Corporation's shares ever split?
Incyte Corporation's shares were
split on a 2:1 basis on 31 August 2000
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.
Incyte Corporation share price volatility
Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as $53.56 up to $83.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 0.676. This would suggest that Incyte Corporation's shares are less volatile than average (for this exchange).
Incyte Corporation overview
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Frequently asked questions
null What percentage of Incyte Corporation is owned by insiders or institutions? Currently 2.007% of Incyte Corporation shares are held by insiders and 100.655% by institutions.How many people work for Incyte Corporation? Latest data suggests 2,617 work at Incyte Corporation.When does the fiscal year end for Incyte Corporation? Incyte Corporation's fiscal year ends in December.Where is Incyte Corporation based? Incyte Corporation's address is: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803What is Incyte Corporation's ISIN number? Incyte Corporation's international securities identification number is: US45337C1027What is Incyte Corporation's CUSIP number? Incyte Corporation's Committee on Uniform Securities Identification Procedures number is: 45337C102
Looking to invest in AI stocks? Here are some of the best artificial intelligence stocks available, along with tips to better understand AI investments.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
